GLP-1 medications linked to a lower risk of dementia and addiction but higher risk of kidney, pancreatic, and gastrointestinal issues. Demand for weight-loss medications, including popular brands like Ozempic and Wegovy,

As demand for weight-loss injections sold under brand names such as Ozempic and Wegovy continues to soar, a study has uncovered neurological and behavioral health benefits amid risks for pancreatitis and kidney disease.

The newest weight-loss drugs, Wegovy and Zepbound, are incredibly popular. But doctors are still learning about all of the ways they affect the body—both helpful and harmful—beyond reducing weight. In report published in Nature Medicine,

About 140,400 obese patients in Massachusetts were prescribed medications like Wegovy and Zepbound in 2024, a 255 percent increase from 2023, according to a Globe analysis of insurance claims data.

The government is expected to pay lower prices for Ozempic and Wegovy starting in 2027. The Trump administration will decide whether to expand coverage for millions of Americans.

The study revealed that weight-loss drugs significantly benefit neurological and behavioral health, including decreased risks of addiction.

"All these years I thought that thin people -- those people -- just had more willpower," Winfrey said on her podcast.

In a discussion with Oprah, Dr Ania called obesity a disease. She also advised that we should treat obesity like other medical conditions.

Oprah Winfrey says taking a GLP-1 drug such as Ozempic and Wegovy has changed her entire perspective on “thin people.” The media icon, 70, took to her podcast last week to share her experience with an undisclosed type of GLP-1 drug that she began taking in 2023.

Oprah Winfrey shared that weight-loss medications like Ozempic and Wegovy helped her understand the challenges of being thin. After losing nearly 50 pounds, she emphasized that these drugs assist in managing cravings and support a healthier lifestyle amidst her struggles with weight.